NCT01446276

Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease

Long-term Investigation of Resveratrol on Lipid Turnover in Obese Men With Nonalcoholic Fatty Liver Disease. Effects on Liver Fat Content and Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: University of Aarhus · Academic / Other
• Sex: Male
• Age: 25 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate potential metabolic effects of resveratrol in obese healthy men with non-alcoholic fatty liver disease. The investigators hypothesize that resveratrol will: * decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion * decrease liver fat content * increase insulin sensitivity The investigators will look at changes in: * lipid turnover (VLDL-TG kinetics, palmitate kinetics, indirect calorimetry) * liver fat content (MR liver spectroscopy) * insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp) * body composition (DXA and MRI) * lipase activity and fat cell size (fat biopsy from abdominal and femoral adipose tissue)

Conditions

• Obesity
• Nonalcoholic Fatty Liver Disease

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Resveratrol	500 mg 3 times daily for six month
OTHER	Placebo	1 placebo tablet 3 times daily for six month

Timeline

• Start date: 2011-11-01
• Primary completion: 2014-04-01
• Completion: 2014-04-01
• First posted: 2011-10-05
• Last updated: 2014-04-28

Locations

1 site across 1 country: Denmark